- Home
- GNLX vs MOLN Comparison
GNLX vs MOLN Comparison
Compare GNLX & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNLX
- MOLN
- Stock Information
- Founded
- GNLX 2001
- MOLN 2004
- Country
- GNLX United States
- MOLN Switzerland
- Employees
- GNLX N/A
- MOLN N/A
- Industry
- GNLX Biotechnology: Pharmaceutical Preparations
- MOLN
- Sector
- GNLX Health Care
- MOLN
- Exchange
- GNLX Nasdaq
- MOLN Nasdaq
- Market Cap
- GNLX 128.0M
- MOLN 142.5M
- IPO Year
- GNLX 2023
- MOLN 2021
- Fundamental
- Price
- GNLX $7.70
- MOLN $3.75
- Analyst Decision
- GNLX Strong Buy
- MOLN Hold
- Analyst Count
- GNLX 5
- MOLN 1
- Target Price
- GNLX $17.40
- MOLN $4.00
- AVG Volume (30 Days)
- GNLX 232.9K
- MOLN 2.0K
- Earning Date
- GNLX 11-13-2025
- MOLN 03-12-2026
- Dividend Yield
- GNLX N/A
- MOLN N/A
- EPS Growth
- GNLX N/A
- MOLN N/A
- EPS
- GNLX N/A
- MOLN N/A
- Revenue
- GNLX N/A
- MOLN $856,302.00
- Revenue This Year
- GNLX N/A
- MOLN N/A
- Revenue Next Year
- GNLX N/A
- MOLN $1,000.00
- P/E Ratio
- GNLX N/A
- MOLN N/A
- Revenue Growth
- GNLX N/A
- MOLN N/A
- 52 Week Low
- GNLX $1.99
- MOLN $3.36
- 52 Week High
- GNLX $8.27
- MOLN $6.63
- Technical
- Relative Strength Index (RSI)
- GNLX 73.82
- MOLN 51.45
- Support Level
- GNLX $7.05
- MOLN $3.53
- Resistance Level
- GNLX $8.26
- MOLN $3.92
- Average True Range (ATR)
- GNLX 0.68
- MOLN 0.09
- MACD
- GNLX 0.17
- MOLN -0.01
- Stochastic Oscillator
- GNLX 82.75
- MOLN 46.81
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.
About MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.